Kymera Therapeutics announced its Q1 2026 financial results, highlighting ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected by mid and late 2027. The FDA granted Fast Track status to KT-621 for moderate to severe asthma. KT-579 is in Phase 1 trials with data expected in the second half of 2026. Gilead Sciences licensed KT-200, triggering a $45 million milestone payment, with IND planned in 2027. Kymera holds $1.55 billion in cash, supporting operations into 2029 and continues to advance its pipeline with a focus on oral small molecule degraders for immunological diseases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
